Your browser doesn't support javascript.
Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan.
Ko, Ko; Takahashi, Kazuaki; Nagashima, Shintaro; E, Bunthen; Ouoba, Serge; Hussain, Md Razeen Ashraf; Akita, Tomoyuki; Sugiyama, Aya; Sakaguchi, Takemasa; Tahara, Hidetoshi; Ohge, Hiroki; Ohdan, Hideki; Kubo, Tatsuhiko; Ishikawa, Nobuhisa; Takafuta, Toshiro; Fujii, Yoshiki; Mimori, Michi; Okada, Fumie; Kishita, Eisaku; Ariyoshi, Kunie; Kuwabara, Masao; Tanaka, Junko.
  • Ko K; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • Takahashi K; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • Nagashima S; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • E B; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • Ouoba S; Payment Certification Agency, Ministry of Health, Phnom Penh, Cambodia.
  • Hussain MRA; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • Akita T; Unité de Recherche Clinique de Nanoro (URCN), Institut de Recherche en Science de la Santé (IRSS), Nanoro, Burkina Faso.
  • Sugiyama A; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • Sakaguchi T; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • Tahara H; Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • Ohge H; Department of Virology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Ohdan H; Department of Cellular and Molecular Biology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Kubo T; Department of Infectious Diseases, Hiroshima University Hospital, Hiroshima, Japan.
  • Ishikawa N; Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Takafuta T; Department of Public Health and Health Policy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Fujii Y; Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
  • Mimori M; Hiroshima City Funairi Citizens Hospital, Hiroshima, Japan.
  • Okada F; Hiroshima City Institute of Public Health, Hiroshima, Japan.
  • Kishita E; Hiroshima City Health and Welfare Bureau, Hiroshima, Japan.
  • Ariyoshi K; Hiroshima Prefectural Health and Welfare Bureau, Hiroshima, Japan.
  • Kuwabara M; Hiroshima Prefectural Health and Welfare Bureau, Hiroshima, Japan.
  • Tanaka J; Hirishima Prefectural Technology Research Institute Health and Environment Center, Hiroshima, Japan.
Sci Rep ; 12(1): 2419, 2022 02 14.
Article in English | MEDLINE | ID: covidwho-1684100
ABSTRACT
This study aimed to develop the feasible and effective universal screening strategy of the notable SARS-CoV-2 variants by Sanger Sequencing Strategy and then practically applied it for mass screening in Hiroshima, Japan. A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened for the notable SARS-CoV-2 variants (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.1, C.37, B.1.1.529, etc.). The targeted spike region is amplified by nested RT-PCR using in-house designed primer set hCoV-Spike-A and standard amplification protocol. Additionally, randomly selected 96 samples were also amplified using primer sets hCoV-Spike-B and hCoV-Spike-C. The negative amplified samples were repeated for second attempt of amplification by volume-up protocol. Thereafter, the amplified products were assigned for Sanger sequencing using corresponding primers. The positive amplification rate of primer set hCoV-Spike-A, hCoV-Spike-B and hCoV-Spike-C were 87.3%, 83.3% and 93.8% respectively for standard protocol and increased to 99.6%, 95.8% and 96.9% after second attempt by volume-up protocol. The readiness of genome sequences was 96.9%, 100% and 100% respectively. Among 48 mutant isolates, 26 were B.1.1.7 (Alpha), 7 were E484K single mutation and the rest were other types of mutation. Moreover, 5 cluster cases with single mutation at N501S were firstly reported in Hiroshima. This study indicates the reliability and effectiveness of Sanger sequencing to screen large number of samples for the notable SARS-CoV-2 variants. Compared to the Next Generation Sequencing (NGS), our method introduces the feasible, universally applicable, and practically useful tool for identification of the emerging variants with less expensive and time consuming especially in those countries where the NGS is not practically available. Our method allows not only to identify the pre-existing variants but also to examine other rare type of mutation or newly emerged variants and is crucial for prevention and control of pandemic.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Mass Screening / Sequence Analysis, DNA / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Randomized controlled trials Topics: Variants Limits: Humans Country/Region as subject: Asia Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-04952-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Mass Screening / Sequence Analysis, DNA / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Randomized controlled trials Topics: Variants Limits: Humans Country/Region as subject: Asia Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-04952-2